铁石心肠

China approves first-ever drug for acute mountain sickness prevention_我的网站

一 |     

    Medicine File photo: VCG
China has granted marketing approval of its first drug for the prevention of acute mountain sickness, filling the long-standing gap in the domestic market where no such medications had been available, Science and Technology Daily reported on Tuesday.
The National Medical Products Administration (NMPA) has approved the marketing of acetazolamide sustained-release capsules, the report said. As the first specialized drug in China indicated for preventing of acute mountain sickness, its approval marks the end of the country's lack of dedicated preventive treatment for altitude illness. 
By inhibiting the activity of carbonic anhydrase, acetazolamide promotes the renal excretion of bicarbonate, corrects respiratory alkalosis caused by hypoxia at high altitudes, thereby regulating acid-base balance, optimizing respiratory status, elevating blood oxygen levels, and reducing the risk of onset at the source. 
In contrast to health products that only provide auxiliary regulatory effects, this medication has been validated through stringent clinical trials and stands as a specialized drug approved by the NMPA with a clear indication for prevention, said the report.
Led by principal investigator is Luobu Gesang, a deputy dean of the People's Hospital of Xizang Autonomous Region, the clinical trial was designed by his team and has yielded critical evidence to inform prevention strategies for altitude sickness that are specifically adapted to Chinese and Asian populations. 
"Previously, although acetazolamide had already been used internationally for the prevention of acute mountain sickness, China had long lacked an NMPA-approved acetazolamide formulation supported by rigorous clinical trials. Furthermore, the existing international formulations were short-acting tablets requiring multiple daily doses, and no drugs with the relevant indication were available on the domestic market for an extended period," said Luobu Gesang.
The sustained-release capsule approved this time not only fills this critical gap but also optimizes the dosage form, providing more reliable and convenient medication protection for the physical health and life safety of people entering high-altitude areas, he added.
Clinical trials showed that, compared with the placebo group, the incidence of acute mountain sickness in the medication group was significantly reduced, with the incidence of moderate-to-severe acute mountain sickness decreasing by 14.6 percent, according to the report.
Related research has been published in the international flagship journal of high-altitude medicine, High Altitude Medicine & Biology.
Global Times
。1月12日：索尼移动正在重组，包括新的领导层和新的战略。索尼移动营销副总裁Don Mesa在接受外国媒体采访时表示，“我们经历了许多变化，我们业务的每个组成部分都受到了影响。

二 | ”重组预示着索尼移动将采取新的战略。

三 | Kimio Maki被任命为索尼非常成功的相机部门的新开发总监，并在确立索尼为顶级相机制造商方面发挥了重要作用。这似乎非常明智，尤其是因为相机是现代智能手机的重要组成部分。梅萨说，索尼希望提供“更好的相机体验”，但没有详细说明细节。据说Xperia XZ4将成为索尼的首款三摄像头手机。”“我们将在MWC发布产品，”MESA确认。

四 | 我们正在展示的将是我们前进方向的第一步。“5G是一个挑战，”梅萨说。有些人可能不买新设备，因为他们在等5g，但我们不想着急。

五 | 经验一定很好。

六 | ”但是，有一些关于Xperia XZ4 Compact的坏消息。”“我们一直在推动紧凑型系列很长时间，因为它很容易使用，”梅萨解释说。需要不同的尺寸，但人们现在想要更多的屏幕区域来显示内容。”Mesa的话似乎意味着Xperia Compact系列已经被削减，将来可能不会重复。如果不是出乎意料的话，索尼应该在2月份的mwc会议上发布xperia xz4，在该机器的渲染被曝光后，众所周知该机器有21:9的全屏显示。

Current article:http://qu6.shengyaodanrongchui.buzz/list_n9l5xbn/vw9oh9j.html

Published on:02:29:41